ONC Stock Forecast & Price Target

BeOne Medicines is compelling fundamentally because Brukinsa remains a highly durable growth engine, generating about $1.39B in 3Q26 global revenue, up 34% Y/Y, while management said it leads new patient starts in CLL and continues gaining share beyond CLL into WM and MCL. The company also showed improving operating leverage, with 3Q26 total revenue of $1.9B, diluted EPS of $3.28, and $5.87B in cash, while raising full-year revenue guidance to $6.9B-$7.0B and operating income to $1.2B-$1.3B. Beyond Brukinsa, a 50+ drug pipeline with 96 ongoing clinical trials, plus advancing solid-tumor assets such as GPC3 x 4-1BB, PRMT5i, and CEA ADC, supports a broader long-term growth profile and reduces dependence on a single product.

BeOne Medicines is fundamentally challenged by heavy dependence on BRUKINSA, which generated 74% of total revenue in 2025, leaving the business highly exposed to any slowdown in its core BTK franchise. The bear case also highlights meaningful pipeline risk: sonro may fail to show efficacy or face a new safety signal in Phase 3, while the broader platform success rate is modeled at just 5%, with more than 50 drugs still in clinical trials. On top of clinical and regulatory uncertainty, competition from AbbVie and AstraZeneca, plus the risk of significant cash burn and geopolitical concerns tied to being a Chinese biotech, weaken the company’s long-term fundamental outlook.